Immunocytochemical characterization of cell lines from human malignant mesothelioma: characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies.
A panel of nine monoclonal antibodies was used to characterize human mesothelioma cell lines that we established from human malignant mesothelioma. The antigens detected were cytokeratin, vimentin, epithelial membrane antigen, carcinoembryonic antigen, Leu-M1 (CD15), desmin, factor VIII-related antigen (von Willebrand factor antigen), OV632, and ME1, a specific monoclonal antibody directed against human malignant mesothelioma. The technique used was the alkaline phosphatase anti-alkaline phosphatase method. All 30 cell lines, either epithelial, sarcomatous, or mixed, showed strong reactivity with cytokeratin and vimentin antibodies. None of the cell lines demonstrated any reactivity with carcinoembryonic antigen, Leu-M1, or factor VIII antibodies; moreover, all of 22 cell lines studied were positive for ME1 antibody and 10 of 12 cell lines studied were positive for OV632. Some interesting features were noted: only two of the 30 cell lines presented a weak positive staining with epithelial membrane antigen, and nine of 19 cell lines tested demonstrated a cytoplasmic staining pattern with desmin antibody. These results show that established human mesothelioma cell lines still possess the immunocytochemical characteristics that are basically consistent with the immunohistochemical features described in tumor tissues of malignant mesothelioma. These characteristics can be used to identify the mesothelioma cells grown from human malignant mesothelioma. Hence, the mesothelioma cell lines will provide a useful tool for the investigation of the cell biology of the tumor and the mechanisms of mesothelial cell transformation, as well as the in vitro evaluation of the effects of some drugs in order to develop new therapies for malignant mesothelioma.
Zeng
L
L
Laboratoire de Pathologie Cellulaire et Moléculaire de l'Environnement INSERM U139, C.H.U. Henri Mondor, Créteil, France.
Fleury-Feith
J
J
Monnet
I
I
Boutin
C
C
Bignon
J
J
Jaurand
M C
MC
D000199:Actins / Q000032:analysis / Q000276:immunology; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000032:analysis / Q000276:immunology; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis / Q000276:immunology; D002272:Carcinoembryonic Antigen / Q000032:analysis / Q000276:immunology; D002471:Cell Transformation, Neoplastic / Q000473:pathology; D003893:Desmin / Q000032:analysis / Q000276:immunology; D005169:Factor VIII / Q000032:analysis / Q000276:immunology; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D007633:Keratins / Q000032:analysis / Q000276:immunology; D008297:Male; D008562:Membrane Glycoproteins / Q000032:analysis / Q000276:immunology; D008654:Mesothelioma / Q000737:chemistry* / Q000175:diagnosis / Q000473:pathology*; D008875:Middle Aged; D018396:Mucin-1; D014407:Tumor Cells, Cultured; D014746:Vimentin / Q000032:analysis / Q000276:immunology; D014841:von Willebrand Factor / Q000032:analysis / Q000276:immunology
D000199:Actins; D000911:Antibodies, Monoclonal; D015214:Antigens, Differentiation, Myelomonocytic; D002272:Carcinoembryonic Antigen; D003893:Desmin; D008562:Membrane Glycoproteins; D018396:Mucin-1; D014746:Vimentin; D014841:von Willebrand Factor; D007633:Keratins; D005169:Factor VIII